| Radiant Care Hospice Llc 1740 Marco Polo Way Suite 9, Burlingame, CA, 94010 | |
| (800) 610-4153 |
News Archive
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
Melanoma is one of the less common types of skin cancer but it accounts for the majority of the skin cancer deaths (about 75 percent).The five-year survival rate for early stage melanoma is very high (98 percent), but the rate drops precipitously if the cancer is detected late or there is recurrence.So a great deal rides on the accuracy of the initial surgery, where the goal is to remove as little tissue as possible while obtaining "clean margins" all around the tumor.So far no imaging technique has been up to the task of defining the melanoma's boundaries accurately enough to guide surgery.Instead surgeons tend to cut well beyond the visible margins of the lesion in order to be certain they remove all the malignant tissue.Two scientists at Washington University in St. Louis have developed technologies that together promise to solve this difficult problem.
British scientists say they have made a breakthrough in their development of a bird flu drug that could treat humans in the event of an outbreak.
In a step toward better diagnosis and treatment of digestive conditions, such as inflammatory bowel disease, scientists report in ACS Biomaterials & Engineering that they have developed a first-of-its-kind collagen-based membrane for use in microchips.
This issue includes a feature on designer DNA-binding proteins to combat viral infections in agriculture and medicine; news items include updates of official opening of the Okayama University Silicon Valley Office at Fremont (CA), and international collaboration work with Xiamen University; research highlights on immunizing plants; identification of gene Vrn-D4 for enabling wheat to adapt to areas with warm winters; importance of introgression on intra-specific genetic differentiation and adaptive divergence; an interesting twist on supercooled liquid water; and manufacturing denim in Okayama.
› Verified 4 days ago
| Name | Radiant Care Hospice Llc |
|---|---|
| Location | 1740 Marco Polo Way Suite 9, Burlingame, California |
| Hospice ID | 921540 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| Accreditation Provider | Community Health Accreditation Partner (CHAP) |
| SSA county code | 510 |
News Archive
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
Melanoma is one of the less common types of skin cancer but it accounts for the majority of the skin cancer deaths (about 75 percent).The five-year survival rate for early stage melanoma is very high (98 percent), but the rate drops precipitously if the cancer is detected late or there is recurrence.So a great deal rides on the accuracy of the initial surgery, where the goal is to remove as little tissue as possible while obtaining "clean margins" all around the tumor.So far no imaging technique has been up to the task of defining the melanoma's boundaries accurately enough to guide surgery.Instead surgeons tend to cut well beyond the visible margins of the lesion in order to be certain they remove all the malignant tissue.Two scientists at Washington University in St. Louis have developed technologies that together promise to solve this difficult problem.
British scientists say they have made a breakthrough in their development of a bird flu drug that could treat humans in the event of an outbreak.
In a step toward better diagnosis and treatment of digestive conditions, such as inflammatory bowel disease, scientists report in ACS Biomaterials & Engineering that they have developed a first-of-its-kind collagen-based membrane for use in microchips.
This issue includes a feature on designer DNA-binding proteins to combat viral infections in agriculture and medicine; news items include updates of official opening of the Okayama University Silicon Valley Office at Fremont (CA), and international collaboration work with Xiamen University; research highlights on immunizing plants; identification of gene Vrn-D4 for enabling wheat to adapt to areas with warm winters; importance of introgression on intra-specific genetic differentiation and adaptive divergence; an interesting twist on supercooled liquid water; and manufacturing denim in Okayama.
› Verified 4 days ago
| NPI Number | 1093192932 |
| Organization Name | Radiant Care Hospice Llc |
| Address | 1740 Marco Polo Way Burlingame, California, 94010 |
| Phone Number | (800)610-4153 |
News Archive
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
Melanoma is one of the less common types of skin cancer but it accounts for the majority of the skin cancer deaths (about 75 percent).The five-year survival rate for early stage melanoma is very high (98 percent), but the rate drops precipitously if the cancer is detected late or there is recurrence.So a great deal rides on the accuracy of the initial surgery, where the goal is to remove as little tissue as possible while obtaining "clean margins" all around the tumor.So far no imaging technique has been up to the task of defining the melanoma's boundaries accurately enough to guide surgery.Instead surgeons tend to cut well beyond the visible margins of the lesion in order to be certain they remove all the malignant tissue.Two scientists at Washington University in St. Louis have developed technologies that together promise to solve this difficult problem.
British scientists say they have made a breakthrough in their development of a bird flu drug that could treat humans in the event of an outbreak.
In a step toward better diagnosis and treatment of digestive conditions, such as inflammatory bowel disease, scientists report in ACS Biomaterials & Engineering that they have developed a first-of-its-kind collagen-based membrane for use in microchips.
This issue includes a feature on designer DNA-binding proteins to combat viral infections in agriculture and medicine; news items include updates of official opening of the Okayama University Silicon Valley Office at Fremont (CA), and international collaboration work with Xiamen University; research highlights on immunizing plants; identification of gene Vrn-D4 for enabling wheat to adapt to areas with warm winters; importance of introgression on intra-specific genetic differentiation and adaptive divergence; an interesting twist on supercooled liquid water; and manufacturing denim in Okayama.
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | Not Available | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | Not Available | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | Not Available | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | Not Available | 97.3 |
| Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
Melanoma is one of the less common types of skin cancer but it accounts for the majority of the skin cancer deaths (about 75 percent).The five-year survival rate for early stage melanoma is very high (98 percent), but the rate drops precipitously if the cancer is detected late or there is recurrence.So a great deal rides on the accuracy of the initial surgery, where the goal is to remove as little tissue as possible while obtaining "clean margins" all around the tumor.So far no imaging technique has been up to the task of defining the melanoma's boundaries accurately enough to guide surgery.Instead surgeons tend to cut well beyond the visible margins of the lesion in order to be certain they remove all the malignant tissue.Two scientists at Washington University in St. Louis have developed technologies that together promise to solve this difficult problem.
British scientists say they have made a breakthrough in their development of a bird flu drug that could treat humans in the event of an outbreak.
In a step toward better diagnosis and treatment of digestive conditions, such as inflammatory bowel disease, scientists report in ACS Biomaterials & Engineering that they have developed a first-of-its-kind collagen-based membrane for use in microchips.
This issue includes a feature on designer DNA-binding proteins to combat viral infections in agriculture and medicine; news items include updates of official opening of the Okayama University Silicon Valley Office at Fremont (CA), and international collaboration work with Xiamen University; research highlights on immunizing plants; identification of gene Vrn-D4 for enabling wheat to adapt to areas with warm winters; importance of introgression on intra-specific genetic differentiation and adaptive divergence; an interesting twist on supercooled liquid water; and manufacturing denim in Okayama.
› Verified 4 days ago
| Home Health Aides | 1 |
| Counselors | 1 |
| Homemakers | 1 |
| Licensed Practical or Vocational Nurses | 1 |
| Medical Social Workers | 1 |
| Physicians | 1 |
| Registered Nurses | 1 |
| Total Employees | 7 |
|---|
News Archive
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
Melanoma is one of the less common types of skin cancer but it accounts for the majority of the skin cancer deaths (about 75 percent).The five-year survival rate for early stage melanoma is very high (98 percent), but the rate drops precipitously if the cancer is detected late or there is recurrence.So a great deal rides on the accuracy of the initial surgery, where the goal is to remove as little tissue as possible while obtaining "clean margins" all around the tumor.So far no imaging technique has been up to the task of defining the melanoma's boundaries accurately enough to guide surgery.Instead surgeons tend to cut well beyond the visible margins of the lesion in order to be certain they remove all the malignant tissue.Two scientists at Washington University in St. Louis have developed technologies that together promise to solve this difficult problem.
British scientists say they have made a breakthrough in their development of a bird flu drug that could treat humans in the event of an outbreak.
In a step toward better diagnosis and treatment of digestive conditions, such as inflammatory bowel disease, scientists report in ACS Biomaterials & Engineering that they have developed a first-of-its-kind collagen-based membrane for use in microchips.
This issue includes a feature on designer DNA-binding proteins to combat viral infections in agriculture and medicine; news items include updates of official opening of the Okayama University Silicon Valley Office at Fremont (CA), and international collaboration work with Xiamen University; research highlights on immunizing plants; identification of gene Vrn-D4 for enabling wheat to adapt to areas with warm winters; importance of introgression on intra-specific genetic differentiation and adaptive divergence; an interesting twist on supercooled liquid water; and manufacturing denim in Okayama.
› Verified 4 days ago
| Radiant Care Hospice Llc Location: 1740 Marco Polo Way Suite 9, Burlingame, California, 94010 Phone: (800) 610-4153 |